Kishimoto C, Takada H, Kuroki Y, Matsushita I, Hiraoka Y, Kurokawa M, Ochiai H, Sasayama S
Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Cardiovasc Res. 1993 Feb;27(2):243-8. doi: 10.1093/cvr/27.2.243.
The aim was to test the efficacy of the immune system modulator lobenzarit disodium in the treatment of coxsackievirus B3 myocarditis.
Two week old C3H/He mice were inoculated with 10(3) plaque forming units of coxsackievirus B3. Lobenzarit disodium, 25 mg.kg-1.d-1, was given subcutaneously daily on days 0-14 (experiment I; group 2) and days 14-28 (experiment II; group 4). Both treated groups were compared to infected controls for each experiment (groups 1 and 3). For the analysis of splenic lymphocyte subsets, additional mice in untreated and treated groups were killed on d 7, and the percentages of Thy 1.2 (CD3), L3T4 (CD4), Ly 2 (CD8) subsets were analysed by laser flow cytometry (experiment III).
In experiment I, the survival rate in the lobenzarit treated group was significantly lower than in the controls (2/11 v 8/11). Cellular infiltration and myocardial necrosis in the lobenzarit group were more severe. Myocardial virus titres and serum neutralising antibody titres did not differ significantly between the two groups. In experiment II, the survival rate (7/9 v 13/13) and cardiac pathology between the two groups did not differ significantly. In experiment III, the percentage of the Thy 1.2 subset (CD3) in the treated group was significantly lower (p < 0.05) than in the control group, at 36.0(SD 2.9)% v 42.8(5.8)%.
Lobenzarit disodium decreased splenic pan T cells and aggravated both clinical course and cardiac pathology in acute murine coxsackievirus B3 myocarditis.
旨在测试免疫系统调节剂苯扎利特二钠治疗柯萨奇病毒B3心肌炎的疗效。
给两周龄的C3H/He小鼠接种10³空斑形成单位的柯萨奇病毒B3。在第0 - 14天（实验I；第2组）和第14 - 28天（实验II；第4组）每天皮下给予苯扎利特二钠，剂量为25 mg·kg⁻¹·d⁻¹。将两个治疗组与每个实验的感染对照组（第1组和第3组）进行比较。为了分析脾脏淋巴细胞亚群，在第7天处死未治疗组和治疗组中的额外小鼠，通过激光流式细胞术分析Thy 1.2（CD3）、L3T4（CD4）、Ly 2（CD8）亚群的百分比（实验III）。
在实验I中，苯扎利特治疗组的存活率显著低于对照组（2/11对8/11）。苯扎利特组的细胞浸润和心肌坏死更严重。两组之间的心肌病毒滴度和血清中和抗体滴度无显著差异。在实验II中，两组之间的存活率（7/9对13/13）和心脏病理学无显著差异。在实验III中，治疗组中Thy 1.2亚群（CD3）的百分比显著低于对照组（p < 0.）
